Rockfish Bio

Rockfish Bio is a biotech spin-off of the University for Natural Resources and Life Sciences, Vienna and the Medical University of Vienna that is centred on the development of senolytic compounds based on a newly discovered target pathway. Our target pathway was successfully tested in 7 different cell types with a therapeutic index of up to 700. Our lead candidate RFB01016 was able to restore neuromuscular functions and massively extend the health and life span (+40 % median survival time after start of treatment) in naturally aged mice. Proof-of-concept studies in several preclinical disease models are currently ongoing. This will demonstrate the efficacy of our approach for the treatment of age-related diseases and help us in the selection process for our first lead indication. First results from stroke and chronic kidney disease models show outstanding efficacy of our lead compound. Privacy Policy and Imprint can be accessed by clicking "Learn more"